Table 6.
Multivariate analysis of effect of GRB2 expression on survival (based on data from clinical samples).
| Unadjusted | Adjusted | ||||
|---|---|---|---|---|---|
| HR (95%CI) | p value | HR (95%CI) | p value | p valuea | |
| GRB2 | 3.603 (1.865–6.960) | 1.360e−04*** | 2.058 (1.004–4.215) | 4.859e−02* | 6.800e−04*** |
| Age | 0.999 (0.952–1.048) | 9.564e−01 | 0.992 (0.943–1.045) | 7.726e−01 | 1.000e+00 |
| iPSA | 1.000 (1.000–1.000) | 2.094e−02* | 1.000 (0.999–1.000) | 1.859e−01 | 1.047e−01 |
| GS | 1.085 (0.930–1.267) | 2.999e−01 | 0.176 (1.004–1.378) | 4.468e−02* | 1.000e+00 |
| T category | 1.559 (1.314–1.849) | 3.449e−07*** | 1.489 (1.244–1.782) | 1.415e−05*** | 1.725e−06*** |
GRB2 cut off, z-score ≥ 1; iPSA: initial PSA: GS: Gleason score; “*” and “***” indicate p value < 0.05 and < 0.001, respectively. aAdjusted p value (using a Bonferroni correction).